International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
Children and adolescents who regularly consume sugar-sweetened beverages (SSBs) and fruit juice may face a…
Women who consistently performed resistance training had a substantially lower risk of major cardiovascular disease…
US Adults with prediabetes who participated in an intensive lifestyle intervention had a significantly lower…
The impact of late-life high blood pressure (BP) on dementia risk appears to depend on…
A U.S. study found that receiving the recombinant herpes zoster vaccine (RZV, shingles vaccine) was…
A pooled analysis of 11 prospective cohort studies involving more than 1.5 million adults found…
This website uses cookies.